{"entity":{"id":"nct07162714","kind":"trial","name":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","aka":["STAR"],"tldr":"A phase 2 trial of ivonescimab in colorectal cancer, run by Zhejiang Cancer Hospital, now recruiting.","summary":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer is a phase 2, interventional study registered as NCT07162714 by Zhejiang Cancer Hospital, with a registry enrolment figure of 30 participants, started 2025-10-27 and due to reach its primary completion in 2027-03-31. Interventions recorded: radiotherapy; Ivonescimab (20mg/kg Q3W); Non-operative Management; Surgery. Conditions listed: Rectal Cancer; Radiation; AK112. Primary outcome: Complete remission rate (CR rate). Colorectal eligibility wording from the registry: \"Histopathologically confirmed rectal adenocarcinoma, without any prior anti - tumor treatment; The status of MMR/MSI is detected by IHC/PCR in pathological biopsy to clarify that the patient's classification is pMMR/MSS;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07162714","url":"https://clinicaltrials.gov/study/NCT07162714"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["ivonescimab"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07162714","phase":"2","setting":"Short-Course Radiotherapy Followed by Ivonescimab (AK112) in pMMR/MSS Mid-Low Rectal Cancer: An Exploratory Phase II Clinical Study.","sponsor":"Zhejiang Cancer Hospital","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07162714/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}